ctDNA-Based Adjuvant Chemotherapy for High-Risk Rectal Cancer

The goal of this clinical trial is to investigate whether adjuvant chemotherapy can prevent disease recurrence in patients with high-risk rectal cancer who have detectable ctDNA after surgery. The main research question the REACT study aims to answer is: \- Does adjuvant chemotherapy improve disease-free survival in patients with high-risk rectal cancer with detectable ctDNA after surgery? Interventions: \- Patients with detectable ctDNA after surgery and randomised to the experimental group will be offered adjuvant chemotherapy (4 cycles CAPOX/6 cycles FOLFOX) within 12 weeks after surger

Trial Details

NCT ID
NCT07188025
Phase
PHASE3
Sponsor
Erasmus Medical Center
Status
RECRUITING
Cancer Type
Colorectal Cancer
Interventions
  • Adjuvant chemotherapy
Locations (sample)
  • 's-Hertogenbosch, Netherlands|51.69917,5.30417
  • Almelo, Netherlands|52.35667,6.6625
  • Amersfoort, Netherlands|52.155,5.3875
  • Amsterdam, Netherlands|52.37403,4.88969
  • Breda, Netherlands|51.58656,4.77596

Key Eligibility Criteria

  • Detectable ctDNA in the postoperative blood sample
  • Age ≥ 18 years
  • WHO performance score 0-1
  • Informed consent for PLCRC with specific consent for additional blood withdrawals and offering of future experimental research

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Colorectal Cancer Trials on Trialify →